Search

Your search keyword '"Koopmanschap, Marc"' showing total 84 results
Start Over Author "Koopmanschap, Marc" Language undetermined
84 results on '"Koopmanschap, Marc"'

1. Effects of the DICE Method to Improve Timely Recognition and Treatment of Neuropsychiatric Symptoms in Early Alzheimer’s Disease at the Memory Clinic: The BEAT-IT Study

Author

Eikelboom, Willem S., van den Berg, Esther, Coesmans, Michiel, Goudzwaard, Jeannette A., Koopmanschap, Marc, Lazaar, Najoua, van Bruchem-Visser, Rozemarijn L., Driesen, Jan J. M., den Heijer, Tom, Hoogers, Susanne, de Jong, Frank Jan, Mattace-Raso, Francesco, Thomeer, Elsbeth C., Vrenken, Suzanne, Vroegindeweij, Lilian J. H. M., Zuidema, Sytse U., Singleton, Ellen H., van Swieten, John C., Ossenkoppele, Rik, and Papma, Janne M.

Subjects
Psychiatry and Mental health, Clinical Psychology, General Neuroscience, General Medicine, Geriatrics and Gerontology
Abstract

Background: Neuropsychiatric symptoms (NPS) are highly prevalent in Alzheimer’s disease (AD) and are associated with negative outcomes. However, NPS are currently underrecognized at the memory clinic and non-pharmacological interventions are scarcely implemented. Objective: To evaluate the effectiveness of the Describe, Investigate, Create, Evaluate (DICE) method™ to improve the care for NPS in AD at the memory clinic. Methods: We enrolled sixty community-dwelling people with mild cognitive impairment or AD dementia and NPS across six Dutch memory clinics with their caregivers. The first wave underwent care as usual (n = 36) and the second wave underwent the DICE method (n = 24). Outcomes were quality of life (QoL), caregiver burden, NPS severity, NPS-related distress, competence managing NPS, and psychotropic drug use. Reliable change index was calculated to identify responders to the intervention. A cost-effectiveness analysis was performed and semi-structured interviews with a subsample of the intervention group (n = 12). Results: The DICE method did not improve any outcomes over time compared to care as usual. Half of the participants of the intervention group (52%) were identified as responders and showed more NPS and NPS-related distress at baseline compared to non-responders. Interviews revealed substantial heterogeneity among participants regarding NPS-related distress, caregiver burden, and availability of social support. The intervention did not lead to significant gains in quality-adjusted life years and well-being years nor clear savings in health care and societal costs. Conclusion: The DICE method showed no benefits at group-level, but individuals with high levels of NPS and NPS-related distress may benefit from this intervention.

Published
2023
Full Text
View/download PDF

3. Additional file 1 of E-nergEYEze, a vision-specific eHealth intervention based on cognitive behavioral therapy and self-management to reduce fatigue in adults with visual impairment: study protocol for a randomized controlled trial

Author

Veldman, Manon H. J., van der Aa, Hilde P. A., Bode, Christina, Knoop, Hans, Hulshof, Carel T. J., Koopmanschap, Marc, Stavleu, Edwin, van Rens, Ger H. M. B., and van Nispen, Ruth M. A.

Abstract

Additional file 1. Overview measurements [59, 60].

Published
2021
Full Text
View/download PDF

4. Efficacy of halopeRIdol to decrease the burden of Delirium In adult Critically ill patiEnts (EuRIDICE): study protocol for a prospective randomised multi-centre double-blind placebo-controlled clinical trial in the Netherlands

Author

Smit, Lisa, Trogrlic, Zoran, Devlin, JW, Osse, R.J., Ponssen, H, Slooter, AJC, Hunfeld, Nicole, Rietdijk, Wim, Gommers, Diederik, van der Jagt, Mathieu, Boogaard, M, Brouwers, A, Lens, JA, van der Meer, BJM, Schoonderbeek, FJ, Simons, KS, Berger, E, Bouman, A, Del Campo, M, van Duijn, Ditty, Embden-van Donk, H, de Graaf, D, Hoogendoorn, E, Ormskerk, Patricia, Roovers, N, Toscano, E, Vileito, Alicija, van Zuylen, T, Exler, Claartje, van den Berg, Esther, van Meeteren, Jetty, Koopmanschap, Marc, Intensive Care, Psychiatry, Pharmacy, Neurology, Rehabilitation Medicine, Health Technology Assessment (HTA), Clinical sciences, and Neuroprotection & Neuromodulation

Subjects
intensive & critical care, Adult, medicine.medical_specialty, delirium & cognitive disorders, Placebo, behavioral disciplines and activities, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Double-Blind Method, Intensive care, mental disorders, medicine, Haloperidol, therapeutics, critical illness, Humans, Multicenter Studies as Topic, Prospective Studies, adult intensive & critical care, Netherlands, Randomized Controlled Trials as Topic, Coma, Haloperidol/adverse effects, business.industry, Intensive Care, Delirium, adult neurology, General Medicine, Guideline, Checklist, Clinical trial, Intensive Care Units, Emergency medicine, Medicine, medicine.symptom, business, Delirium/drug therapy, mental health, medicine.drug
Abstract

IntroductionDelirium in critically ill adults is associated with prolonged hospital stay, increased mortality and greater cognitive and functional decline. Current practice guideline recommendations advocate the use of non-pharmacological strategies to reduce delirium. The routine use of scheduled haloperidol to treat delirium is not recommended given a lack of evidence regarding its ability to resolve delirium nor improve relevant short-term and longer-term outcomes. This study aims to evaluate the efficacy and safety of haloperidol for the treatment of delirium in adult critically ill patients to reduce days spent with coma or delirium.Methods and analysisEuRIDICE is a prospective, multi-centre, randomised, double-blind, placebo-controlled trial. Study population consists of adult intensive care unit (ICU) patients without acute neurological injury who have delirium based on a positive Intensive Care Delirium Screening Checklist (ICDSC) or Confusion Assessment Method for the ICU (CAM-ICU) assessment. Intervention is intravenous haloperidol 2.5 mg (or matching placebo) every 8 hours, titrated daily based on ICDSC or CAM-ICU positivity to a maximum of 5 mg every 8 hours, until delirium resolution or ICU discharge. Main study endpoint is delirium and coma-free days (DCFD) up to 14 days after randomisation. Secondary endpoints include (1) 28-day and 1-year mortality, (2) cognitive and functional performance at 3 and 12 months, (3) patient and family delirium and ICU experience, (4) psychological sequelae during and after ICU stay, (4) safety concerns associated with haloperidol use and (5) cost-effectiveness. Differences in DCFDs between haloperidol and placebo group will be analysed using Poisson regression analysis. Study recruitment started in February 2018 and continues.Ethics and disseminationThe study has been approved by the Medical Ethics Committee of the Erasmus University Medical Centre Rotterdam (MEC2017-511) and by the Institutional Review Boards of the participating sites. Its results will be disseminated via peer-reviewed publication and conference presentations.Trial registrationNCT03628391

Published
2020

5. Additional file 1: of Two versus five days of antibiotics after appendectomy for complex acute appendicitis (APPIC): study protocol for a randomized controlled trial

Author

Boom, Anne Loes Van Den, Wijkerslooth, Elisabeth De, Rosmalen, Joost Van, FrĂŠdĂŠrique Beverdam, Evert-Jan Boerma, Boermeester, Marja, Bosmans, Joanna, Burghgraef, Thijs, Consten, Esther, Imro Dawson, Dekker, Jan Willem, Emous, Marloes, Geloven, Anna Van, Go, Peter, Heijnen, Luc, Huisman, Sander, Pierre, Dayanara Jean, Jonge, Joske De, Kloeze, Jurian, Koopmanschap, Marc, Langeveld, Hester, Luyer, Misha, Melles, Damian, Mouton, Johan, Ploeg, Augustinus Van Der, Poelmann, Floris, Ponten, Jeroen, Rossem, Charles Van, Schreurs, Wilhelmina, JoĂŤl Shapiro, Steenvoorde, Pascal, Toorenvliet, Boudewijn, Verhelst, Joost, Hendt Versteegh, Wijnen, Rene, and Wijnhoven, Bas

Subjects
body regions, nervous system, fungi, food and beverages, humanities
Abstract

Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist APPIC trial. (PDF 129Â kb)

Published
2018
Full Text
View/download PDF

6. Additional file 2: of Two versus five days of antibiotics after appendectomy for complex acute appendicitis (APPIC): study protocol for a randomized controlled trial

Author

Boom, Anne Loes Van Den, Wijkerslooth, Elisabeth De, Rosmalen, Joost Van, FrĂŠdĂŠrique Beverdam, Evert-Jan Boerma, Boermeester, Marja, Bosmans, Joanna, Burghgraef, Thijs, Consten, Esther, Imro Dawson, Dekker, Jan Willem, Emous, Marloes, Geloven, Anna Van, Go, Peter, Heijnen, Luc, Huisman, Sander, Pierre, Dayanara Jean, Jonge, Joske De, Kloeze, Jurian, Koopmanschap, Marc, Langeveld, Hester, Luyer, Misha, Melles, Damian, Mouton, Johan, Ploeg, Augustinus Van Der, Poelmann, Floris, Ponten, Jeroen, Rossem, Charles Van, Schreurs, Wilhelmina, JoĂŤl Shapiro, Steenvoorde, Pascal, Toorenvliet, Boudewijn, Verhelst, Joost, Hendt Versteegh, Wijnen, Rene, and Wijnhoven, Bas

Abstract

Subject information and consent form (in Dutch). (PDF 231Â kb)

Published
2018
Full Text
View/download PDF

7. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries

Author

Franken, Margreet, Stolk, Elly, Scharringhausen, Tessa, de Boer, Anthonius, Koopmanschap, Marc, Dep Farmaceutische wetenschappen, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology, Dep Farmaceutische wetenschappen, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology, Health Technology Assessment (HTA), and Health Economics (HE)

Subjects
Economic growth, Drug reimbursement, macromolecular substances, Disease, Scientific literature, Severity of Illness Index, Reimbursement Mechanisms, Disease severity, Belgium, Taverne, Medicine, Humans, Cost Sharing, Policy Making, Reimbursement, Health policy, Netherlands, Sweden, Actuarial science, business.industry, Health Policy, The Netherlands, Insurance, Pharmaceutical Services, Willingness to use, Transparency (graphic), France, business, Medical need
Abstract

Considerations beyond cost-effectiveness are important in reimbursement decision making. We assessed the importance of disease severity in drug reimbursement decision making in Belgium, France, The Netherlands and Sweden. We investigated scientific literature and policy documents and conducted three interviews in each country (four in The Netherlands) with persons involved in drug reimbursement. Disease severity is an important consideration, especially where the level is high. The Netherlands operationalizes disease severity using the proportional shortfall approach. Sweden uses categories to give an indication of the level of severity. In The Netherlands and Sweden, severity only implicitly plays a role in the decision whether to reimburse a drug, whereas in Belgium and France it also explicitly plays a role in determining the willingness to use public resources. Interviewees acknowledged that as well as a qualitative description of the disease, quantitative information may also be useful as input for decision making. None of them, however, considered this to be of decisive importance. Although disease severity is important in drug reimbursement decision making in all four countries, all seem to struggle in explicitly specifying its actual role. Belgium and France are the most explicit by using levels of severity in setting reimbursement levels; all four countries could, however, improve the transparency of its actual importance relative to the other criteria in the decision-making process.

Published
2014

8. Governance of conditional reimbursement practices in The Netherlands

Author

Boon, W.P.C., Martins, Luis, Koopmanschap, Marc, Innovation and Sustainability, Innovation Studies, Innovation and Sustainability, Innovation Studies, and Health Technology Assessment (HTA)

Subjects
Orphan Drug Production, Process (engineering), Cost-Benefit Analysis, Drug reimbursement, Orphan drug, Reimbursement Mechanisms, Politics, Taverne, Production (economics), Orphan drugs, Humans, Drug Approval, Health policy, Reimbursement, Netherlands, Government, Actuarial science, Corporate governance, Health Policy, Conditional approvals, Legislation, Drug, Government Regulation, Pharmaceuticals, Business, Decision making
Abstract

When entering the market, orphan drugs are associated with substantial prices and a high degree of uncertainty regarding safety and effectiveness. This makes decision making about the reimbursement of these drugs a complex exercise. To advance on this, the Dutch government introduced a conditional reimbursement trajectory that requires a re-evaluation after four years. This article focuses on the origins, governance and outcomes of such a conditional reimbursement trajectory for orphan drugs. We find that the conditional reimbursement scheme is the result of years of discussion and returning public pressure about unequal access to expensive drugs. During the implementation of the scheme the actors involved went through a learning process about the regulation. Our analysis shows that previous collaborations or already existing organisational structures led to faster production of the required data on cost-effectiveness. However, cost-effectiveness evidence resulting from additional research seems to weigh less than political, judicial and ethical considerations in decision making on reimbursement of orphan drugs in the Netherlands.

Published
2014

13. Evaluatie Proeftuin Farmacie Groningen

Author

Goossensen, Anne, Koopmanschap, Marc, Grit, Kor, de Mul, Marleen, Koolman, AHE, Zijlstra, P, Health Services Management & Organisation (HSMO), and Erasmus School of Health Policy & Management

Published
2007

23. Economic valuation of informal care

Author

van den Berg, B (Bernard), Brouwer, Werner, Koopmanschap, Marc, and Erasmus School of Health Policy & Management

Published
2004

24. Mantelzorg: een goed om te waarderen

Author

van Exel, Job, van den Berg, B (Bernard), Koopmanschap, Marc, Brouwer, Werner, and Erasmus School of Health Policy & Management

Published
2004

36. Costing in economic evaluations

Author

Brouwer, Werner, Rutten, FFH, Koopmanschap, Marc, Drummond, M., McGuire, A., and Erasmus School of Health Policy & Management

Published
2001

39. Directe kosten van gezondheidszorg

Author

Rutten, FFH, Oostenbrink, JB (Jan), Koopmanschap, Marc, Rutten- van Mölken, M.P.M.H., van Busschbach, J.J., Rutten, F.F.H., and Erasmus School of Health Policy & Management

Published
2000

47. Economische evaluatie

Author

Bleichrodt, Han, Koopmanschap, Marc, Lapre, R., Rutten, F., Schut, E., Health Economics (HE), and Erasmus School of Health Policy & Management

Published
1999

49. Costs of dementia in the Netherlands

Author

Koopmanschap, Marc, Polder, JJ (Johan), Meerding, WJ (Willem Jan), Bonneux, L (Luc), Maas, Paul, Wimo, A., Jönsson, B., Karlsson, G., Winblad, B., Erasmus School of Health Policy & Management, and Public Health

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results